CY1482A - Phenethanolamine derivatives - Google Patents

Phenethanolamine derivatives

Info

Publication number
CY1482A
CY1482A CY1482A CY148289A CY1482A CY 1482 A CY1482 A CY 1482A CY 1482 A CY1482 A CY 1482A CY 148289 A CY148289 A CY 148289A CY 1482 A CY1482 A CY 1482A
Authority
CY
Cyprus
Prior art keywords
phenethanolamine derivatives
phenethanolamine
derivatives
Prior art date
Application number
CY1482A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27449465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1482(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB838310477A external-priority patent/GB8310477D0/en
Priority claimed from GB838317087A external-priority patent/GB8317087D0/en
Priority claimed from GB838329568A external-priority patent/GB8329568D0/en
Priority claimed from GB848401889A external-priority patent/GB8401889D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY1482A publication Critical patent/CY1482A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1742—Unsaturated ethers containing halogen containing six-membered aromatic rings with halogen atoms bound to the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1782—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
CY1482A 1983-04-18 1989-12-08 Phenethanolamine derivatives CY1482A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB838310477A GB8310477D0 (en) 1983-04-18 1983-04-18 Chemical compounds
GB838317087A GB8317087D0 (en) 1983-06-23 1983-06-23 Chemical compounds
GB838329568A GB8329568D0 (en) 1983-11-04 1983-11-04 Chemical compounds
GB848401889A GB8401889D0 (en) 1984-01-25 1984-01-25 Chemical compounds

Publications (1)

Publication Number Publication Date
CY1482A true CY1482A (en) 1989-12-08

Family

ID=27449465

Family Applications (1)

Application Number Title Priority Date Filing Date
CY1482A CY1482A (en) 1983-04-18 1989-12-08 Phenethanolamine derivatives

Country Status (37)

Country Link
US (5) US4992474A (de)
JP (2) JPS63264443A (de)
KR (1) KR920004186B1 (de)
AR (3) AR244199A1 (de)
AT (1) AT390611B (de)
AU (1) AU573212B2 (de)
BE (1) BE899448A (de)
BG (1) BG61490B2 (de)
CA (2) CA1335999C (de)
CH (2) CH661497A5 (de)
CY (1) CY1482A (de)
CZ (1) CZ285602B6 (de)
DE (4) DE3448452C2 (de)
DK (2) DK167493B1 (de)
ES (2) ES8505641A1 (de)
FI (1) FI85011C (de)
FR (1) FR2545482B1 (de)
GB (2) GB2140800B (de)
GR (1) GR79925B (de)
HK (1) HK36889A (de)
HU (1) HU200160B (de)
IE (1) IE57237B1 (de)
IL (1) IL71569A (de)
IT (1) IT1199112B (de)
KE (1) KE3864A (de)
LU (2) LU85329A1 (de)
MX (1) MX9203226A (de)
MY (1) MY102087A (de)
NL (2) NL188406C (de)
NO (2) NO159016C (de)
NZ (2) NZ221999A (de)
PH (1) PH21574A (de)
PT (1) PT78443B (de)
SE (1) SE462594B (de)
SG (1) SG12289G (de)
SK (1) SK278120B6 (de)
ZW (1) ZW6584A1 (de)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
IL74940A (en) * 1984-04-17 1988-06-30 Glaxo Group Ltd Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them
GB8525321D0 (en) * 1985-10-15 1985-11-20 Glaxo Group Ltd Chemical compounds
US4943591A (en) * 1984-10-17 1990-07-24 Glaxo Group Limited Dichloroaniline derivatives
GB8525484D0 (en) * 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0223410A3 (de) * 1985-10-16 1987-11-19 Glaxo Group Limited Ethanolaminderivate
EP0220054A3 (de) * 1985-10-16 1987-12-02 Glaxo Group Limited Ethanolaminderivate
GB8525483D0 (en) * 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0278727A3 (de) * 1987-02-10 1990-03-14 Glaxo Group Limited 1-(4-Amino-3-chloro-5-trifluoromethylphenyl)-2-(substituierte amino)ethanol-Derivate und ihre Verwendung bei der Behandlung von Lungenkrankheiten
EP0286242A3 (de) * 1987-03-12 1989-08-09 Glaxo Group Limited Ethanolamin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Verbindungen
GB8718940D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
GB8718938D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
DE3880628T2 (de) * 1987-11-13 1993-08-05 Glaxo Group Ltd Phenethanolamin-derivate.
DE3884363T2 (de) * 1987-12-18 1994-01-20 Glaxo Group Ltd Ethanolaminderivate.
ZA889405B (en) * 1987-12-18 1989-12-27 Glaxo Group Ltd Ethanolamine derivatives
GB8909273D0 (en) * 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
GB2230775A (en) * 1989-04-24 1990-10-31 Glaxo Group Ltd Phenethanolamine compounds
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
JPH03178929A (ja) * 1989-09-07 1991-08-02 Glaxo Group Ltd 炎症及びアレルギー治療用化合物
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
DK0416950T3 (da) * 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
PT95542B (pt) * 1989-10-10 1999-09-30 Glaxo Group Ltd Processo para a prparacao de derivados de fenetanolamina
MY105368A (en) 1990-03-02 1994-09-30 Glaxo Group Ltd Inhalation device.
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
AP323A (en) * 1992-05-08 1994-03-07 Glaxo Group Ltd Drug material suitable for micronisation.
GB9215274D0 (en) * 1992-07-17 1992-09-02 Scras Derivatives of(phenylethyl-beta-ol)amine
ES2065269B1 (es) * 1993-05-11 1995-10-01 S A L V A T Lab Sa 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion.
ATE171169T1 (de) * 1993-12-10 1998-10-15 Novartis Ag Substituierte oxazolidine mit stimulierende wirkung auf beta-adrenergic rezeptoren
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
CZ296209B6 (cs) * 1995-04-14 2006-02-15 Glaxo Wellcome Inc. Inhalátor a inhalacní systém
ATE373613T1 (de) 1995-04-14 2007-10-15 Smithkline Beecham Corp Verfahren zur herstellung eines dosierinhalators
TR199701168T1 (xx) 1995-04-14 1998-05-21 Glaxo Wellcome Inc. Flutikazon Propionat i�in �l��lm�� doz inhaleri.
PL180880B1 (pl) * 1995-04-14 2001-04-30 Glaxo Wellcome Inc Inhalator z dozymetrem
EP0947498B1 (de) * 1996-12-02 2004-09-15 Chisso Corporation Optisch aktive nitroalkohol-derivate, optisch aktive aminoalkohol-derivate und verfahren zu ihrer herstellung
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
WO1999062451A1 (en) * 1998-06-01 1999-12-09 Verbiscar Anthony J Topical transdermal treatments
ES2142771B1 (es) * 1998-09-28 2001-01-01 Vita Invest Sa Nuevos derivados de la 6-(4-fenil-butoxi) hexilamina y procedimiento para la obtencion de salmeterol.
AU4417500A (en) 1999-04-14 2000-11-14 Glaxo Group Limited Pharmaceutical aerosol formulation
ATE447952T1 (de) * 1999-08-21 2009-11-15 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0014546D0 (en) * 2000-06-14 2000-08-09 Glaxo Group Ltd A novel process
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AR032361A1 (es) * 2000-08-05 2003-11-05 Glaxo Group Ltd Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
JP2004509031A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド フルオロカーボンポリマーで２回以上コーティングした定量式吸入缶
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
JP4446661B2 (ja) * 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、１７α位に環状エステル基を有するアンドロスタンの１７β−カルボチオ酸エステル誘導体
WO2002098404A1 (en) * 2001-06-01 2002-12-12 Tendskin Company Topical compositions for veterinary uses
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
EP1429751A1 (de) * 2001-09-14 2004-06-23 Boehringer Ingelheim Pharma GmbH & Co.KG Salicylsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel
PT1425001E (pt) 2001-09-14 2009-02-18 Glaxo Group Ltd Derivados de fenetanolamina para o tratamento de doenças respiratórias
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10209583B4 (de) * 2002-03-05 2006-01-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 4-(6-Bromhexyloxy)-butylbenzol
US6835857B2 (en) 2002-03-05 2004-12-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene
WO2003088961A1 (en) * 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
JP2005523920A (ja) * 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
DE10249576B3 (de) * 2002-10-24 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (R)-Salbutamol
GB0225030D0 (en) * 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225535D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20060076010A1 (en) * 2002-12-18 2006-04-13 King Michael L Drug delivery system with vented mouthpiece
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
WO2004106333A1 (en) * 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2005016410A2 (en) 2003-08-11 2005-02-24 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
GB0319826D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Process
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
EP1694655A2 (de) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
AU2004294889B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
GB0329182D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1732526A2 (de) * 2004-03-12 2006-12-20 Cipla Ltd. Salmeterol-formulierungen zur inhalation
CN1984876A (zh) * 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
EP1778638A1 (de) * 2004-07-21 2007-05-02 Theravance, Inc. Adrenergische diaryl ether beta2-rezeptoragonisten
JP2008512470A (ja) * 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
EP1949891A1 (de) 2004-10-12 2008-07-30 Generics (UK) Limited Verfahren zur Herstellung von Suspensionsaerosolformulierungen, wobei die Partikel durch Fällung im Innenkanister gebildet werden
EP1811981B1 (de) 2004-10-12 2008-08-13 Merck Generics (UK) Limited Verfahren zur herstellung von suspensionsaerosolformulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005033732B4 (de) * 2005-05-27 2014-02-13 Grünenthal GmbH Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007045857A1 (en) * 2005-10-17 2007-04-26 Generics (Uk) Limited Novel process
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
WO2007079466A2 (en) * 2006-01-04 2007-07-12 Nano Mist International, Llc Air driven delivery system for sprayable media
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US20070219223A1 (en) * 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
JP5399902B2 (ja) 2006-08-22 2014-01-29 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
US20080319086A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched salmeterol
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2009134524A2 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
EP2662046B1 (de) * 2008-05-09 2023-03-15 Nuvaira, Inc. Systeme und Baugruppen zur Behandlung eines Bronchialbaumes
EP2127641A1 (de) * 2008-05-26 2009-12-02 Inke, S.A. Mikronisierbare Form von Salmeterolxinafoat
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (de) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one für die Behandlung von Lungenfunktion
EP2228368A1 (de) 2009-03-12 2010-09-15 Almirall, S.A. Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
AR076621A1 (es) * 2009-05-29 2011-06-22 Pearl Therapeutics Inc Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN107049479B (zh) 2009-10-27 2020-10-16 努瓦拉公司 具有可冷却的能量发射组件的递送装置
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
KR101820542B1 (ko) 2009-11-11 2018-01-19 호라이라 인코포레이티드 조직을 치료하고 협착을 제어하기 위한 방법, 기구 및 장치
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2012014114A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
CA2812319A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP2578570A1 (de) 2011-10-07 2013-04-10 Almirall, S.A. Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
EP2641900A1 (de) 2012-03-20 2013-09-25 Almirall, S.A. Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors
CN103864629A (zh) * 2012-12-13 2014-06-18 天津金耀集团有限公司 昔萘酸沙美特罗的精制方法
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
CN105188679B (zh) 2013-03-15 2018-10-16 珍珠治疗公司 用于微粒晶体材料的状态调节的方法和系统
PT2815739T (pt) 2013-06-17 2020-01-13 Arven Ilac Sanayi Ve Ticaret As Método de enchimento de composição de inalação
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
US9447067B2 (en) 2014-10-03 2016-09-20 Amphastar Pahmaceuticals, Inc. Method of preparing intermediate of salmeterol
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt
CA3226153A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
WO2024006226A1 (en) * 2022-06-26 2024-01-04 Alexander Shulgin Research Institute, Inc. N-substituted phenylalkylamines and their use as therapeutic agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1451357A (fr) * 1965-07-01 1966-01-07 Soc Ind Fab Antibiotiques Sifa Nouveaux alcools dérivés de l'éthano-9, 10 dihydro-9, 10 anthracene et procédé de préparation
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1321701A (en) * 1969-10-01 1973-06-27 Continental Pharma Amino-alcohols their salts and process for prepairing the same
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
US3879442A (en) * 1972-07-27 1975-04-22 Warner Lambert Co 5-hydroxy-{60 (substituted aminomethyl)-mu-xylene-{60 ,{60 -diols
GB1511159A (en) * 1975-07-10 1978-05-17 Leo A Amines preparation
US4160036A (en) * 1975-07-29 1979-07-03 Allen & Hanburys Limited 4-Hydroxy-1,3-benzenedimethanol derivatives
GB1529972A (en) * 1975-07-29 1978-10-25 Allen & Hanburys Ltd Basic alcohols
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
JPS52113934A (en) * 1976-03-19 1977-09-24 Eisai Co Ltd Phenethylamine derivatives and bronchodilator containing the same
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them
DE2833140A1 (de) * 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
US4160367A (en) * 1978-09-11 1979-07-10 General Motors Corporation Dual container additive dispenser for appliance
EP0021636B1 (de) * 1979-06-16 1982-12-01 Beecham Group Plc Sekundäre Amine, ihre Herstellung und Verwendung in pharmazeutischen Zusammensetzungen
FR2460919A1 (fr) * 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
US4288456A (en) * 1980-09-19 1981-09-08 E. R. Squibb & Sons, Inc. Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
EP0103830A3 (de) * 1982-09-22 1985-07-31 Bayer Ag Wachstumsfördernde Phenylethylamin-Derivate
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
IL74940A (en) * 1984-04-17 1988-06-30 Glaxo Group Ltd Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR840009063A (ko) 1984-12-24
ATA129184A (de) 1989-11-15
AU573212B2 (en) 1988-06-02
IT1199112B (it) 1988-12-30
HU200160B (en) 1990-04-28
DE3414752C2 (de) 1993-03-25
IL71569A (en) 1987-10-30
FI85011B (fi) 1991-11-15
AT390611B (de) 1990-06-11
SG12289G (en) 1989-07-07
PT78443B (en) 1986-08-28
NZ221999A (en) 1988-11-29
GR79925B (de) 1984-10-31
LU85329A1 (fr) 1985-06-04
DK175083B1 (da) 2004-05-24
KR920004186B1 (ko) 1992-05-30
JPH0729997B2 (ja) 1995-04-05
BE899448A (fr) 1984-10-18
NZ207885A (en) 1988-11-29
JPH0569817B2 (de) 1993-10-01
NL188406B (nl) 1992-01-16
MX9203226A (es) 1992-07-01
NO1994017I1 (no) 1994-09-22
CH661497A5 (fr) 1987-07-31
DE3414752A1 (de) 1984-10-18
NO841568L (no) 1984-10-19
GB2140800A (en) 1984-12-05
MY102087A (en) 1992-03-31
IT8448064A0 (it) 1984-04-18
NL930066I1 (nl) 1993-09-01
US5126375A (en) 1992-06-30
NL188406C (nl) 1992-06-16
CA1335999C (en) 1995-06-20
FI85011C (fi) 1992-02-25
NO159016C (no) 1988-11-23
DK201784A (da) 1984-10-19
NL8401258A (nl) 1984-11-16
FR2545482A1 (fr) 1984-11-09
PH21574A (en) 1987-12-11
PT78443A (pt) 1984-05-01
GB2140800B (en) 1987-09-23
AR244199A1 (es) 1993-10-29
GB8410124D0 (en) 1984-05-31
GB2176476B (en) 1987-12-31
ES531722A0 (es) 1985-06-01
NL930066I2 (nl) 1993-10-01
JPH0687800A (ja) 1994-03-29
CH667084A5 (fr) 1988-09-15
GB8612357D0 (en) 1986-06-25
SE8402188L (sv) 1984-10-19
SE462594B (sv) 1990-07-23
FI841548A0 (fi) 1984-04-18
AR245687A1 (es) 1994-02-28
US4992474A (en) 1991-02-12
DE19575029I2 (de) 2002-11-07
IE57237B1 (en) 1992-06-17
CZ402891A3 (en) 1993-05-12
JPS63264443A (ja) 1988-11-01
IL71569A0 (en) 1984-07-31
ZW6584A1 (en) 1985-04-17
IE840965L (en) 1984-10-18
DE3448452C2 (de) 1994-01-05
KE3864A (en) 1989-05-19
DK158092D0 (da) 1992-12-30
DK201784D0 (da) 1984-04-18
ES539625A0 (es) 1986-07-16
FR2545482B1 (fr) 1988-06-17
AU2706484A (en) 1984-10-25
DK167493B1 (da) 1993-11-08
BG61490B2 (bg) 1997-09-30
ES8505641A1 (es) 1985-06-01
DE3448338C2 (de) 1993-05-19
LU88265I2 (de) 1994-02-03
GB2176476A (en) 1986-12-31
DK158092A (da) 1992-12-30
US5091422A (en) 1992-02-25
SE8402188D0 (sv) 1984-04-18
SK402891A3 (en) 1995-07-11
CA1336004C (en) 1995-06-20
US5225445A (en) 1993-07-06
SK278120B6 (en) 1996-02-07
AR247721A1 (es) 1995-03-31
US5243076A (en) 1993-09-07
ES8609209A1 (es) 1986-07-16
NO159016B (no) 1988-08-15
FI841548A (fi) 1984-10-19
HK36889A (en) 1989-05-12
CZ285602B6 (cs) 1999-09-15

Similar Documents

Publication Publication Date Title
GB2140800B (en) Phenethanolamine derivatives
GB8334499D0 (en) Derivatives
GB8405980D0 (en) N-pyridylpyrazole derivatives
EP0135177A3 (en) Benzocycloalkane derivatives
EP0129513A3 (en) Oxamic-acid derivatives
GB2145084B (en) Fredericamycin derivatives
GB8416172D0 (en) Spirosuccinide derivatives
GB8415032D0 (en) 3-phenyl-4-cyano-pyrrole derivatives
DE3475621D1 (en) 2-dioxacycloalkylthiopenem derivatives
DE3479730D1 (en) Fluoromethylthiooxacephalosporin derivatives
ZA842875B (en) Phenethanolamine derivatives
GB2146991B (en) Fluorenylalkylimidazole derivatives
EG16589A (en) 2-azacycloalkylthiopenem derivatives
GB2152046B (en) 2-arylbenzothiazoline derivatives
DE3460649D1 (en) Cyanotercyclohexane derivatives
AR243155A1 (es) Procedimiento para la preparacion de nuevas benzamidas n-aminoetil-sustituidas.
ZW13184A1 (en) Phenethylamine derivatives
GB8408128D0 (en) Gonadoliberine derivatives
ZA844923B (en) Spirosuccinimide derivatives
GB8331120D0 (en) Benzaldehyde derivatives
EP0143001A3 (en) Pyrimidoisoquinoline derivatives
EP0125695A3 (en) 2-bromo-1-tetralone derivatives
GB8330260D0 (en) Tetrahydro-beta-carboline derivatives
GB2162845B (en) Phenethanolamine derivatives
GB2141717B (en) 17-aza-androstane derivatives